MedTrace Logo

Safety and Tolerability of Zelquistinel in Normal Human Volunteers

NCT04981561 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-03-12

No results posted yet for this study

Summary

To evaluate the safety and tolerability of single ascending doses of zelquistinel in normal human volunteers

Conditions

Interventions

DRUG

zelquistinel

Single dose of zelquistinel

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Syndeio Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Aaron Koenig, MD · Syndeio Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-09
Primary Completion
2017-12-21
Completion
2017-12-21
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04981561 on ClinicalTrials.gov